Filtered By:
Cancer: Epithelial Cancer
Management: Insurance

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Disparities in clinical trial participation in ovarian cancer: A real-world analysis
CONCLUSION: In this national cohort study, only 5% of patients with ovarian cancer participated in clinical drug trials. Interventions are needed to decrease race, ethnicity, and insurance disparities in clinical trial participation.PMID:37300995 | DOI:10.1016/j.ygyno.2023.05.066
Source: Gynecologic Oncology - June 10, 2023 Category: Cancer & Oncology Authors: Anna Jo Bodurtha Smith Rafael Alvarez Jonathan Heintz Fiona Simpkins Emily M Ko Source Type: research

Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database
CONCLUSIONS: For patients with early stage EOC administration of adjuvant chemotherapy within 6 weeks from surgery was associated with better overall survival, especially for those with stage IC disease.PMID:35667901 | DOI:10.1016/j.ygyno.2022.05.015
Source: Cancer Control - June 6, 2022 Category: Cancer & Oncology Authors: Dimitrios Nasioudis Spyridon A Mastroyannis Emily M Ko Ashley F Haggerty Lori Cory Robert L Giuntoli Sarah H Kim Mark A Morgan Nawar A Latif Source Type: research

Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for all GI Cancers?
J Clin Oncol. 2022 Jun 1:JCO2102764. doi: 10.1200/JCO.21.02764. Online ahead of print.ABSTRACTUse of germline genetic testing among patients with cancer is increasing because of (1) the availability of multigene panel tests that include multiple cancer susceptibility genes in a single test, (2) decreased costs of these tests and improvements in insurance coverage, and (3) US Food and Drug Administration-approval of genotype-directed therapies such as poly(ADP-ribose) polymerase inhibitors for individuals with certain cancers and pathogenic germline variants in BRCA1 and BRCA2 (with possible benefits with other genes in the...
Source: Clinical Prostate Cancer - June 1, 2022 Category: Cancer & Oncology Authors: Heather Hampel Matthew B Yurgelun Source Type: research

Fight Aging! Newsletter, April 4th 2022
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - April 3, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, March 1st 2021
This study may have important implications for preventing cell senescence and aging-induced tendinopathy, as well as for the selection of novel therapeutic targets of chronic tendon diseases. Our results showed that the treatment of bleomycin, a DNA damaging agent, induced rat patellar TSC (PTSC) cellular senescence. The senescence was characterized by an increase in the senescence-associated β-galactosidase activity, as well as senescence-associated changes in cell morphology. On the other hand, rapamycin could extend lifespan in multiple species, including yeast, fruit flies, and mice, by decelerating DNA damage ...
Source: Fight Aging! - February 28, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, October 7th 2019
In conclusion, our findings link the calcification of the vascular tissue with the expression of FGF23 in the vessels and with the elevation of circulating levels this hormone. Permanently Boosting Levels of Natural Killer Cells in Mice to Increase Cancer Resistance https://www.fightaging.org/archives/2019/09/permanently-boosting-levels-of-natural-killer-cells-in-mice-to-increase-cancer-resistance/ Researchers here demonstrate a very interesting approach to immunotherapy: they introduce engineered stem cells in mice that will give rise to additional natural killer T cells, boosting the capability of the ...
Source: Fight Aging! - October 6, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, August 12th 2019
We examined 9293 individuals from the Copenhagen General Population Study using nuclear magnetic resonance spectroscopy measurements of total cholesterol, free- and esterified cholesterol, triglycerides, phospholipids, and particle concentration. Fourteen subclasses of decreasing size and their lipid constituents were analysed: six subclasses were very low-density lipoprotein (VLDL), one intermediate-density lipoprotein (IDL), three low-density lipoprotein (LDL), and four subclasses were high-density lipoprotein (HDL). Remnant lipoproteins were VLDL and IDL combined. Mean nonfasting cholesterol concentration was 72â...
Source: Fight Aging! - August 11, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, April 30th 2018
In conclusion, in the Framingham Heart Study population, in the last 30 years, disease duration in persons with dementia has decreased. However, age-adjusted mortality risk has slightly decreased after 1977-1983. Consequences of such trends on dementia prevalence should be investigated. Recent Research on the Benefits of Exercise in Later Life https://www.fightaging.org/archives/2018/04/recent-research-on-the-benefits-of-exercise-in-later-life/ A sizable body of work points to the ability of older individuals to continue to obtain benefits through regular physical activity, and particularly in the case ...
Source: Fight Aging! - April 29, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, February 26th 2018
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - February 25, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, September 26th 2016
This study included 647 patients 80 to 106 years of age who had audiometric evaluations at an academic medical center (141 had multiple audiograms). The degree of hearing loss was compared across the following age brackets: 80 to 84 years, 85 to 89 years, 90 to 94 years, and 95 years and older. From an individual perspective, the rate of hearing decrease between 2 audiograms was compared with age. The researchers found that changes in hearing among age brackets were higher during the 10th decade of life than the 9th decade at all frequencies for all the patients (average age, 90 years). Correspondingly, the annual rate of ...
Source: Fight Aging! - September 25, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs